MBI is pleased to announce another milestone in 2024! Both ArtiAid® and ArtiAidPlus® Intra-articular Injection have received marketing authorization from the Saudi Food and Drug Authority.

The global joint injection market is expected to grow steadily at a compound annual growth rate of 6% per year, especially in the Middle East and Africa. MBI’s global certification strategy accelerates market penetration, helping clients shorten product launch timelines by over 50%.